Will Aerie Pharmaceuticals, Inc. (AERI) Run Out of Steam Soon?

June 21, 2018 - By Adrian Erickson

Investors sentiment decreased to 1.19 in 2018 Q1. Its down 0.01, from 1.2 in 2017Q4. It dived, as 18 investors sold Aerie Pharmaceuticals, Inc. shares while 46 reduced holdings. 17 funds opened positions while 59 raised stakes. 39.43 million shares or 13.11% more from 34.86 million shares in 2017Q4 were reported.
Guggenheim Limited Liability Company has 0% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Quantbot Techs L P holds 0% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 15 shares. Alliancebernstein Limited Partnership owns 0.02% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 436,759 shares. Neuberger Berman Grp Inc Inc Limited Liability Company owns 320,500 shares or 0.02% of their US portfolio. 45,076 are held by Pointstate L P. Pictet Asset Mngmt has 521,992 shares. Geode Capital Limited Com stated it has 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Finance Consulate accumulated 0.3% or 10,500 shares. Qs Lc reported 2,100 shares or 0% of all its holdings. National Bank & Trust Of New York Mellon has 0.01% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Jpmorgan Chase Co holds 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) or 7,619 shares. California State Teachers Retirement Systems reported 51,826 shares stake. Vanguard Grp Inc has invested 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Moreover, Principal Gp has 0% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Bamco New York accumulated 14,769 shares or 0% of the stock.

Since May 21, 2018, it had 2 buys, and 4 sales for $13.13 million activity. Kopczynski Casey C. sold $646,237 worth of stock or 11,000 shares. The insider Cagle Gerald D. bought 1,000 shares worth $49,450.

The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) hit a new 52-week high and has $70.41 target or 7.00 % above today’s $65.80 share price. The 5 months bullish chart indicates low risk for the $2.60B company. The 1-year high was reported on Jun, 21 by Barchart.com. If the $70.41 price target is reached, the company will be worth $181.93 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 0.15% or $0.1 during the last trading session, reaching $65.8. About 80,623 shares traded. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has declined 8.48% since June 21, 2017 and is downtrending. It has underperformed by 21.05% the S&P500.

Analysts await Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) to report earnings on August, 7. They expect $-0.96 EPS, down 17.07 % or $0.14 from last year’s $-0.82 per share. After $-1.05 actual EPS reported by Aerie Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -8.57 % EPS growth.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

Among 6 analysts covering Aerie Pharma (NASDAQ:AERI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharma has $8700 highest and $7700 lowest target. $80.83’s average target is 22.84% above currents $65.8 stock price. Aerie Pharma had 10 analyst reports since January 2, 2018 according to SRatingsIntel. As per Wednesday, May 9, the company rating was maintained by Mizuho. Stifel Nicolaus maintained the stock with “Buy” rating in Tuesday, January 2 report. The rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, February 28. As per Wednesday, May 9, the company rating was maintained by H.C. Wainwright. Cantor Fitzgerald maintained the stock with “Buy” rating in Tuesday, May 8 report. The rating was maintained by Canaccord Genuity on Wednesday, January 24 with “Buy”. The firm has “Buy” rating given on Thursday, March 29 by Mizuho. As per Thursday, March 1, the company rating was maintained by H.C. Wainwright. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given on Friday, February 16 by H.C. Wainwright.

More news for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) were recently published by: Gurufocus.com, which released: “Aerie Pharmaceuticals Inc (AERI) CEO Vicente Jr Anido Sold $9.3 million of Shares” on June 09, 2018. Streetinsider.com‘s article titled: “Aerie Pharma (AERI): Early Physician Rhopressa Feedback is Cautiously Positive – Cowen” and published on May 24, 2018 is yet another important article.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. The company has market cap of $2.60 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It currently has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: